Lacosamide Solution
Product Images NDC 72162-2637

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 72162-2637). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Extended Label (72162 2637 02extendedlabel)

A text panel instructing to discard any unused product remaining after 6 months of first opening the bottle, with a blank space labeled "Date Bottle Opened:" followed by lines for entering the date.*

FDA Label Image

Lacosamide-fig-1 (Lacosamide Fig 1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing seizure reduction percentages between placebo and Lacosamide across three studies. The y-axis represents seizure reduction as a median percentage change from baseline, ranging from 0% to 45%. The x-axis groups data by study and dose in mg/day. Results show higher median seizure reduction for Lacosamide doses compared to placebo in each study group.*

FDA Label Image

Lacosamide-fig-2 (Lacosamide Fig 2)

A line graph illustrating the proportion of patients by responder rate (equal to or greater) for Lacosamide and placebo groups in clinical studies 2, 3, and 4. The x-axis shows the percent of patients, while the y-axis represents responder rate from -100% (worsening) to 100% (improvement). Four lines compare placebo and various Lacosamide dosages (200 mg/day and 400 mg/day) with different patient group sizes indicated in the legend.*

FDA Label Image

Lacosamide-fig-3 (Lacosamide Fig 3)

A Kaplan-Meier survival plot illustrating the proportion of patients over time (days) for two groups: Placebo (solid line) and Vimpat (dashed line). The graph shows patient retention declining over approximately 170 days, with Vimpat maintaining a higher proportion compared to Placebo. The plot includes a risk table below the x-axis and statistics including p-value 0.001, hazard ratio 0.548, and 95% confidence interval [0.381, 0.788].*

FDA Label Image

Lacosamide-structure (Lacosamide Structure)

Chemical structure of lacosamide, the active ingredient in Lacosamide oral solution. The diagram depicts the molecular arrangement including amide groups and a benzyl substituent characteristic of lacosamide.*

FDA Label Image

Label (Lbl721622637)

Label for Lacosamide Oral Solution, USP 10 mg/mL by Bryant Ranch Prepack. The label includes dosage strength 10 mg/mL, a volume of 200 mL, and mentions manufacturer MSN Pharmaceuticals Inc. Storage instructions and a note to dispense the medication guide are also visible. Barcodes and QR codes are present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.